Zobrazeno 1 - 10
of 146
pro vyhledávání: '"GUIDO FRANCINI"'
Autor:
Edoardo Francini, Fang-Shu Ou, Stefano Lazzi, Roberto Petrioli, Andrea G. Multari, Guido Pesola, Luciana Messuti, Elena Colombo, Virginia Livellara, Serena Bazzurri, Sara Cherri, Salvatora T. Miano, Eric G. Wolfe, Steven R. Alberts, Joleen M. Hubbard, Harry H. Yoon, Guido Francini
Publikováno v:
Translational Oncology, Vol 14, Iss 2, Pp 100973- (2021)
Background: High tumor infiltrating lymphocytes (TILs) density was previously shown to be associated with favorable prognosis for patients with colon cancer (CC). However, the impact of TILs on overall survival (OS) of stage II CC patients who receiv
Externí odkaz:
https://doaj.org/article/bb727b9e9ca8480e8ece3bee7ce744b5
Autor:
Michele Caraglia, Pierpaolo Correale, Rocco Giannicola, Nicoletta Staropoli, Cirino Botta, Pierpaolo Pastina, Antonello Nesci, Nadia Caporlingua, Edoardo Francini, Laura Ridolfi, Enrico Mini, Giandomenico Roviello, Domenico Ciliberto, Rita Maria Agostino, Alessandra Strangio, Domenico Azzarello, Valerio Nardone, Antonella Falzea, Salvatore Cappabianca, Marco Bocchetti, Graziella D'Arrigo, Giovanni Tripepi, Pierfrancesco Tassone, Raffaele Addeo, Antonio Giordano, Luigi Pirtoli, Guido Francini, Pierosandro Tagliaferri
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Background: GOLFIG is a chemo-immunotherapy regimen established in preclinical models that combines gemcitabine + FOLFOX (fluoropyrimidine backbone coupled to oxaliplatin) poly-chemotherapy with low-dose s. c. recombinant interleukin-2 (rIL-2) and gr
Externí odkaz:
https://doaj.org/article/7170bd6fde8f4eec8eb14aa1cf9dfeb1
Autor:
Alessia D'Ignazio, Vinno Savelli, Pamela Torre, Guido Francini, Roberto Petrioli, Marco Farsi, Edoardo Francini, Franco Roviello, Martina Chirra, Maria Raffaella Ambrosio, Calomino N, Daniele Marrelli, Remo Vernillo
Publikováno v:
Surgical Oncology. 32:2-7
Purpose In this prospective observational study, we sought to compare the efficacy and safety of docetaxel + oxaliplatin + capecitabine (DOC) with epirubicin + oxaliplatin + 5-fluouracil (EOF) as neoadjuvant chemotherapy (NAC) for clinical T3 or T4 n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eddd43311e3c0f99843367b340832558
https://doi.org/10.1016/j.suronc.2019.10.002
https://doi.org/10.1016/j.suronc.2019.10.002
Autor:
Grace Shaw, Pier Vitale Nuzzo, Edoardo Francini, Pietro Rosellini, Celestia S. Higano, Miguel Gonzalez-Velez, Irene Moreno-Candilejo, Francesca Crivelli, Antonio Cigliola, Richard M. Lee-Ying, Guido Francini, Lauren C. Harshman, Christopher Sweeney, Francesco Montagnani, Jesus Garcia-Foncillas, Alan H. Bryce, Jaime Rubio-Perez, Li Zhang, Roberto Petrioli, Nimira S. Alimohamed, Daniel Y.C. Heng, Carmelo Bengala
Publikováno v:
JAMA Network Open
Key Points Question Do patients receiving abiraterone acetate with prednisone as first-line therapy for the treatment of metastatic castration-resistant prostate cancer with bone metastases benefit from the addition of bone resorption inhibitors? Fin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d64af351dfc66c7c9a99a2092482287
http://europepmc.org/articles/PMC8299314
http://europepmc.org/articles/PMC8299314
Autor:
Edoardo Francini, Virginia Livellara, Steven R. Alberts, Guido Francini, Guido Pesola, Eric G. Wolfe, Fang-Shu Ou, Joleen M. Hubbard, Elena Colombo, Sara Cherri, Roberto Petrioli, Luciana Messuti, Stefano Lazzi, Salvatora Tindara Miano, Harry H. Yoon, Andrea Giovanni Multari, Serena Bazzurri
Publikováno v:
Translational Oncology
Translational Oncology, Vol 14, Iss 2, Pp 100973-(2021)
Translational Oncology, Vol 14, Iss 2, Pp 100973-(2021)
Highlights • Low CD3+ TILs rate was associated with shorter OS in those with stage II colon cancer who did not receive adjuvant therapy. • CD3+ TILs rate was not prognostic for patients with stage II colon cancer who had adjuvant therapy. • Low
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::086c6df88bf100ea58efd73d926f72a5
http://europepmc.org/articles/PMC7750416
http://europepmc.org/articles/PMC7750416
We report the case of a heavily pretreated male subject affected by left funiculus liposarcoma and successfully treated with eribulin mesylate. After three surgical interventions, radiotherapy on the lesion of the penile bulb for satellite nodules an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e0a3ce702bcfbd3d9903a7cfe7b6df1
http://hdl.handle.net/11365/1095201
http://hdl.handle.net/11365/1095201
Autor:
Loretta Paolelli, Guido Pesola, Pamela Torre, Ignazio Martellucci, Salvatora Tindara Miano, Guido Francini, Giovanni Paganini, Roberto Petrioli, Edoardo Francini
Objectives The aim of this study was to evaluate the efficacy and safety of the combination Gemcitabine (Gem) plus nab-Paclitaxel (NabP) (Gem/NabP), followed by maintenance Gem in older adults with locally advanced or metastatic pancreatic cancer (PC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d92c41d6b6a2eeb16042f626927f5bfa
http://hdl.handle.net/2158/1210191
http://hdl.handle.net/2158/1210191
Autor:
Guido Francini, Edoardo Francini, Silvano Giorgi, Luca Volterrani, Eleonora Cesqui, Maria Antonietta Mazzei, Roberto Petrioli, Francesco Gentili
The aim of this retrospective study was to detail the main clinicopathological characteristics of advanced cancer patients exhibiting hyperprogressive disease (HPD) during immune checkpoint inhibitor (ICI) nivolumab as second- or third-line treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fdacf629b64b8b3a068d8e333447bc5
http://hdl.handle.net/2158/1210186
http://hdl.handle.net/2158/1210186
Publikováno v:
Medical Hypotheses
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31ea990c91eb5e5a5806aaf42aa2d113
http://hdl.handle.net/11365/1120269
http://hdl.handle.net/11365/1120269
Autor:
Anna Ida Fiaschi, Salvatora Tindara Miano, Calomino N, Guido Francini, Remo Vernillo, Vinno Savelli, Marco Farsi, Franco Rovello, Daniele Marrelli, Edoardo Francini, Roberto Petrioli, Sara Cherri
Publikováno v:
Anti-cancer drugs. 31(3)
The aim of this study was to evaluate the efficacy and safety of modified docetaxel, oxaliplatin, capecitabine (DOC) combination chemotherapy, followed by maintenance capecitabine as first-line therapy for patients with metastatic gastric or gastroes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f54ba6d79100b56946717eb44e48f78b
https://pubmed.ncbi.nlm.nih.gov/31850915
https://pubmed.ncbi.nlm.nih.gov/31850915